This week, we will discuss the role of ApoE in determining the subtypes of C3 Glomerulopathy.
This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
Here is a visual take at “Should we treat mild chronic hypertension during pregnancy?” by Dr. Anand Chellappan
